RXST - NASDAQ
RxSight, Inc.
$4.79
-2.3%RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
At a Glance
Live Snapshotrxst
Total Current Assets
Last Annual Value
287.46M
3-Year CAGR
29%
5-Year CAGR
29%
10-Year CAGR
12%
RxSight, Inc. Competitors Analysis of Total Current Assets
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
RxSight, Inc. NASDAQ:RXST | 287.46M | 19.5% | 10.3% | N/A | |
 OrthoPediatrics Corp. NASDAQ:KIDS | 256.42M | 4.2% | 13.9% | 28.5% | |
 Butterfly Network, Inc. NYSE:BFLY | 249.10M | 2.5% | -13.4% | N/A | |
 Tactile Systems Technology, Inc. NASDAQ:TCMD | 165.17M | 4.4% | 7.8% | 9.9% | |
 Semler Scientific, Inc. NASDAQ:SMLR | 22.69M | -29.9% | -13.0% | 30.4% | |
 Cerus Corporation NASDAQ:CERS | 174.38M | 6.5% | -1.4% | 6.4% | |
 Delcath Systems, Inc. NASDAQ:DCTH | 119.53M | 47.6% | 30.9% | 13.3% | |
 Surmodics, Inc. NASDAQ:SRDX | 81.30M | -2.1% | 3.0% | 3.3% | |
 Treace Medical Concepts, Inc. NASDAQ:TMCI | 132.05M | -12.7% | -0.9% | N/A | |
 DiaMedica Therapeutics Inc. NASDAQ:DMAC | 60.63M | 4.1% | 5.9% | 41.7% | |
 NeuroPace, Inc. NASDAQ:NPCE | 94.07M | 0.5% | -6.7% | N/A |
RxSight, Inc. Fair Value Envelope
Related Guides
Continue your RXST research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.